It is reasonable to speculate that NALPs may be activated in adipose tissue of obese individuals and that these NALPs may contribute to the release of pro-inflammatory IL-1β and IL-18 from adipocytes, the development of the systemic inflammation and the obesity-associated progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). Here, IL18 is linked to metabolic dysfunction-associated steatotic liver disease.